Mucin in cancer: a stealth cloak for cancer cells

키워드

참고문헌 (108)

1. Gum JR Jr, "Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice", Am J Physiol, 276, pp.G666~G676 (1999)
2. Johansson ME, "The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria", Proc Natl Acad Sci U S A, 105, pp.15064~15069 (2008)
3. Boland CR, "Microsatellite instability in colorectal cancer", Gastroenterology, 138, pp.2073~2087 (2010)
4. Kufe DW, "Mucins in cancer : function, prognosis and therapy", Nat Rev Cancer, 9, pp.874~885 (2009)
5. Wahrenbrock M, "Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas", J Clin Invest, 112, pp.853~862 (2003)
6. Smagghe BJ, "MUC1*ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naive state", PLoS One, 8, pp.e58601~ (2013)
7. Mekenkamp LJ, "Mucinous adenocarcinomas : poor prognosis in metastatic colorectal cancer", Eur J Cancer, 48, pp.501~509 (2012)
8. Tran DT, "Mucin-type O-glycosylation during development", J Biol Chem, 288, pp.6921~6929 (2013)
9. Robbe C, "Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract", Biochem J, 384, pp.307~316 (2004)
10. Okudaira K, "MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues", Int J Oncol, 36, pp.765~775 (2010)
11. Niv Y, "Mucin gene expression in the intestine of ulcerative colitis patients : a systematic review and metaanalysis", Eur J Gastroenterol Hepatol, 28, pp.1241~1245 (2016)
12. Hugen N, "Advances in the care of patients with mucinous colorectal cancer", Nat Rev Clin Oncol, 13, pp.361~369 (2016)
13. Day FL, "PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer", Clin Cancer Res, 19, pp.3285~3296 (2013)
14. Garrido-Laguna I, "KRASness and PIK3CAness in patients with advanced colorectal cancer : outcome after treatment with earlyphase trials with targeted pathway inhibitors", PLoS One, 7, pp.e38033~ (2012)
15. Gunal A, "KRAS mutations are associated with specific morphologic features in colon cancer", J Clin Gastroenterol, 47, pp.509~514 (2013)
16. Negri FV, "Thymidylate synthase, topoisomerase-1 and microsatellite instability : relationship with outcome in mucinous colorectal cancer treated with fluorouracil", Anticancer Res, 33, pp.4611~4617 (2013)
17. Nosho K, "PIK3CA mutation in colorectal cancer : relationship with genetic and epigenetic alterations", Neoplasia, 10, pp.534~541 (2008)
18. Pai RK, "BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon : an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features", Am J Surg Pathol, 36, pp.744~752 (2012)
19. Ookawa K, "Transcriptional activation of the MUC2 gene by p53", J Biol Chem, 277, pp.48270~48275 (2002)
20. Pereira MB, "Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues", J Clin Pathol, 54, pp.210~213 (2001)
21. Biemer-Huttmann AE, "Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis", Clin Cancer Res, 6, pp.1909~1916 (2000)
22. Losi L, "Relationship between MUC5AC and altered expression of MLH1protein in mucinous and non-mucinous colorectal carcinomas", Pathol Res Pract, 200, pp.371~377 (2004)
23. Walsh MD, "Expression of MUC2, MUC5AC, MUC5B, and MUC6mucins in colorectal cancers and their association with the CpG island methylator phenotype", Mod Pathol, 26, pp.1642~1656 (2013)
24. Renaud F, "MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer", Int J Cancer, 136, pp.2811~2821 (2015)
25. Rico SD, "Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer", Med Mol Morphol, 54, pp.156~165 (2020)
26. Pothuraju R, "Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance", Mol Cancer, 19, pp.37~ (2020)
27. Jun S, "LIG4 mediates Wnt signalling-induced radioresistance", Nat Commun, 7, pp.10994~ (2016)
28. Jung YS, "TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt", beta-catenin signalling, 2018, pp.20, 1421~1433
29. Jung YS, "TMEM9-v-ATPase activates Wnt", beta-catenin signaling via APC lysosomal degradation for liver regeneration and tumorigenesis, 2021, pp.73, 776~794
30. Wang X, "PAF-Wnt signalinginduced cell plasticity is required for maintenance of breast cancer cell stemness", Nat Commun, 7, pp.10633~ (2016)
31. Dong Y, "MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis", Jpn J Clin Oncol, 50, pp.701~711 (2020)
32. Vincent A, "Epigenetic regulation(DNA methylation, histone modifications)of the 11p15 mucin genes(MUC2, MUC5AC, MUC5B, MUC6)in epithelial cancer cells", Oncogene, 26, pp.6566~6576 (2007)
33. Pigny P, "Identification of a 42-kDa nuclear factor(NF1-MUC5B)from HT-29 MTX cells that binds to the 3' region of human mucin gene MUC5B", Biochem Biophys Res Commun, 220, pp.186~191 (1996)
34. Desseyn JL, "Genomic organization of the 3' region of the human mucin gene MUC5B", J Biol Chem, 272, pp.16873~16883 (1997)
35. Van Seuningen I, "Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells", Biochem J 348 Pt, 3, pp.675~686 (2000)
36. Van Seuningen I, "Transcriptional regulation of the 11p15mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?", Front Biosci, 6, pp.D1216~D1234 (2001)
37. Yuan S, "Long non-coding RNA MUC5B-AS1 promotes metastasis through mutually regulating MUC5B expression in lung adenocarcinoma", Cell Death Dis, 9, pp.450~ (2018)
38. Garcia EP, "MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells", Int J Oncol, 48, pp.2113~2123 (2016)
39. Lahdaoui F, "Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties : implication of the Wnt", beta-catenin pathway, 2017, pp.474, 3733~3746
40. Jung YS, "Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via beta-catenin", Nat Cell Biol, 20, pp.1303~1314 (2018)
41. Sekine A, "Hath1 up-regulates gastric mucin gene expression in gastric cells", Biochem Biophys Res Commun, 344, pp.1166~1171 (2006)
42. Silva EM, "Cadherin-catenin adhesion system and mucin expression : a comparison between young and older patients with gastric carcinoma", Gastric Cancer, 11, pp.149~159 (2008)
43. Pai P, "Mucins and Wnt", beta-catenin signaling in gastrointestinal cancers : an unholy nexus, 2016, pp.37, 223~232
44. Leir SH, "MUC6 mucin expression inhibits tumor cell invasion", Exp Cell Res, 317, pp.2408~2419 (2011)
45. Betge J, "MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer : expression profiles and clinical significance", Virchows Arch, 469, pp.255~265 (2016)
46. Mehla K, "MUC1 : a novel metabolic master regulator", Biochim Biophys Acta, 1845, pp.126~135 (2014)
47. Nath S, "MUC1 : a multifaceted oncoprotein with a key role in cancer progression", Trends Mol Med, 20, pp.332~342 (2014)
48. Li Y, "The epidermal growth factor receptor regulates interaction of the human DF3", MUC1 carcinoma antigen with c-Src and beta-catenin, 2001, pp.276, 35239~35242
49. Schroeder JA, "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogenactivated protein kinase activation in the mouse mammary gland", J Biol Chem, 276, pp.13057~13064 (2001)
50. Schroeder JA, "MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion", Oncogene, 22, pp.1324~1332 (2003)
51. Pochampalli MR, "MUC1 is a novel regulator of ErbB1 receptor trafficking", Oncogene, 26, pp.1693~1701 (2007)
52. Zhang Y, "MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1", PDL1 signaling pathway, 2020, pp.20, 317~
53. Rowse GJ, "Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model", Cancer Res, 58, pp.315~321 (1998)
54. Agata N, "MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8", Cancer Res, 68, pp.6136~6144 (2008)
55. Ren J, "Human MUC1carcinoma-associated protein confers resistance to genotoxic anticancer agents", Cancer Cell, 5, pp.163~175 (2004)
56. Raina D, "The MUC1oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase", Akt and Bcl-xL pathways in rat 3Y1fibroblasts, 2004, pp.279, 20607~20612
57. Yin L, "MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells", Blood, 117, pp.4863~4870 (2011)
58. Yamada N, "MUC1expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells", Cancer Res, 68, pp.2708~2716 (2008)
59. Gendler SJ, "MUC1, the renaissance molecule", J Mammary Gland Biol Neoplasia, 6, pp.339~353 (2001)
60. Lagow EL, "Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha", J Cell Biochem, 86, pp.759~772 (2002)
61. Levitin F, "The MUC1 SEA module is a self-cleaving domain", J Biol Chem, 280, pp.33374~33386 (2005)
62. Zhang L, "Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms", Cancer Immunol Immunother, 62, pp.423~435 (2013)
63. Li Y, "Interaction of glycogen synthase kinase 3beta with the DF3", MUC1 carcinoma-associated antigen and beta-catenin, 1998, pp.18, 7216~7224
64. Wei X, "Human MUC1oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response", Cancer Cell, 7, pp.167~178 (2005)
65. Ahmad R, "MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor", Cancer Res, 69, pp.7013~7021 (2009)
66. Ahmad R, "MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop", Sci Signal, 4, pp.ra9~ (2011)
67. Huang L, "MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation", Cancer Biol Ther, 2, pp.702~706 (2003)
68. Wen Y, "Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin", J Biol Chem, 278, pp.38029~38039 (2003)
69. Wei X, "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha", Mol Cell, 21, pp.295~305 (2006)
70. Pelaseyed T, "Membrane mucins of the intestine at a glance", J Cell Sci, 133 (2020)
71. Shanmugam C, "Prognostic value of mucin 4 expression in colorectal adenocarcinomas", Cancer, 116, pp.3577~3586 (2010)
72. Peignon G, "Complex interplay between beta-catenin signalling and Notch effectors in intestinal tumorigenesis", Gut, 60, pp.166~176 (2011)
73. Carraway KL 3rd, "An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling", J Biol Chem, 274, pp.5263~5266 (1999)
74. Govindarajan B, "Membranetethered mucins have multiple functions on the ocular surface", Exp Eye Res, 90, pp.655~663 (2010)
75. Haridas D, "MUC16 : molecular analysis and its functional implications in benign and malignant conditions", FASEB J, 28, pp.4183~4199 (2014)
76. Gipson IK, "Comparison of the transmembrane mucins MUC1and MUC16 in epithelial barrier function", PLoS One, 9, pp.e100393~ (2014)
77. Aithal A, "MUC16 as a novel target for cancer therapy", Expert Opin Ther Targets, 22, pp.675~686 (2018)
78. 김나영, "Somatic Mutaome Profile in Human Cancer Tissues", Genomics & Informatics, 11(4), pp.239~244 (2013), 한국유전체학회[DOI]
79. Das S, "Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells", Oncotarget, 6, pp.5772~5787 (2015)
80. Giannakouros P, "Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin(CA125)is driven by its cytoplasmic tail", Int J Oncol, 46, pp.91~98 (2015)
81. Hattrup CL, "Structure and function of the cell surface(tethered)mucins", Annu Rev Physiol, 70, pp.431~457 (2008)
82. Belisle JA, "Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16(CA125)", Immunology, 122, pp.418~429 (2007)
83. Belisle JA, "Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes", Mol Cancer, 9, pp.118~ (2010)
84. Felder M, "MUC16(CA125) : tumor biomarker to cancer therapy, a work in progress", Mol Cancer, 13, pp.129~ (2014)
85. Rump A, "Binding of ovarian cancer antigen CA125", MUC16 to mesothelin mediates cell adhesion, 2004, pp.279, 9190~9198
86. Gubbels JA, "Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors", Mol Cancer, 5, pp.50~ (2006)
87. Chen SH, "Mesothelin binding to CA125", MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation, 2013, pp.3, 1870~
88. Komatsu M, "Synthesis and secretion of Muc4", sialomucin complex : implication of intracellular proteolysis, 2002, pp.368, 41~48
89. Albrecht H, "MUC1 and MUC4 : switching the emphasis from large to small", Cancer Biother Radiopharm, 26, pp.261~271 (2011)
90. Boivin M, "CA125(MUC16)tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis", Gynecol Oncol, 115, pp.407~413 (2009)
91. Comamala M, "Downregulation of cell surface CA125", MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH : OVCAR3 ovarian carcinoma cells, 2011, pp.104, 989~999
92. Reinartz S, "CA125(MUC16)gene silencing suppresses growth properties of ovarian and breast cancer cells", Eur J Cancer, 48, pp.1558~1569 (2012)
93. Theriault C, "MUC16(CA125)regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis", Gynecol Oncol, 121, pp.434~443 (2011)
94. Snyder LC, "Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer", Clin Colorectal Cancer, 5(Suppl 2), pp.S71~S80 (2005)
95. Vincenzi B, "Cetuximab : from bench to bedside", Curr Cancer Drug Targets, 10, pp.80~95 (2010)
96. Ling YH, "Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1", S phase arrest in human non-small-cell lung cancer cell lines, 2007, pp.72, 248~258
97. Yano S, "Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition", Anticancer Res, 23, pp.3639~3650 (2003)
98. Sipples R, "Common side effects of anti-EGFR therapy : acneform rash", Semin Oncol Nurs, 22, pp.28~34 (2006)
99. Yin L, "Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress", J Biol Chem, 278, pp.35458~35464 (2003)
100. Cherrin C, "An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo", Cancer Biol Ther, 9, pp.493~503 (2010)
101. Yap TA, "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors", J Clin Oncol, 29, pp.4688~4695 (2011)
102. Kazazi-Hyseni F, "Bevacizumab", Oncologist, 15, pp.819~825 (2010)
103. Stacker SA, "The VEGF signaling pathway in cancer : the road ahead", Chin J Cancer, 32, pp.297~302 (2013)
104. Wood JP, "Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo", Cancer Med, 4, pp.1309~1321 (2015)
105. Dankort D, "A new mouse model to explore the initiation, progression, and therapy of BRAFV600Einduced lung tumors", Genes Dev, 21, pp.379~384 (2007)
106. DuPage M, "Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase", Nat Protoc, 4, pp.1064~1072 (2009)
107. Xu Y, "Inhibition of topoisomerase(DNA)I(TOP1) : DNA damage repair and anticancer therapy", Biomolecules, 5, pp.1652~1670 (2015)
108. George J, "Comprehensive genomic profiles of small cell lung cancer", Nature, 524, pp.47~53 (2015)

관련 논문AI추천